This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe
Home   Membership   Events   Resources   Accreditation Feb. 2, 2011

ACRO 2011: Challenging Issues in Lung and Esophageal Cancer
ACRO    Share   Share on FacebookTwitterShare on LinkedinE-mail article
Feb. 24 to 26, Hotel del Coronado, Coronado, Calif.
Need a review on modern treatment techniques for early-stage and locally advanced lung and esophageal cancers? Then register today for ACRO 2011, which includes a four-hour in-depth plenary session featuring the following faculty and presentations:
  • Modern Developments in the Management of Early Stage Lung Carcinomas
    • Dr. Brian Kavanagh, University of Colorado
    • Dr. Bryan Meyers (surgeon), Washington University in St. Louis
  • Case Studies #2: Surgical and Radiation Issues in the Management of Locally Advanced Lung Cancer
    • Dr. Brian Kavanagh, University of Colorado
    • Dr. Bryan Meyers (surgeon), Washington University in St. Louis
  • The Evolving Role of Surveillance and Surgery After Definitive ChemoRT in Esophageal Carcinoma
    • Dr. Bryan Meyers (surgeon), Washington University in St. Louis
Click here to review the clinical program.

Rogosin investigators use cancer cells to fight cancer
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In an audacious twist on the concept of fighting fire with fire, scientists have developed a provocative strategy of fighting cancer with cancer cells. Researchers at the Rogosin Institute are taking tumor cells from mice, encapsulating them in beads made from a seaweed-derived sugar called agarose, and implanting them in the abdomen of cancer patients. There, cells in the beads secrete proteins researchers believe could signal a patient's cancer to stop growing, shrink or even die. More

Study finds racial disparity in breast cancer outcomes
HealthDay News via Bloomberg Businessweek    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In an ongoing effort to shed light on the reason for racial disparities in breast cancer prognosis, researchers in North Carolina report new findings from their research on black women and breast cancer. Previous research has shown that breast cancer in younger black women in the United States is more likely to be the more aggressive basal-like (triple-negative) subtype, which may help explain why black women are more likely to die from breast cancer than other women. In this new study, researchers analyzed tissue from 518 black women and 631 white women with invasive breast cancer who were enrolled in the Carolina Breast Cancer Study. More

Peer-reviewed articles meant to impact your practice of oncology

Visit The Oncologist’s Community Site to read our virtual collection of Radiation articles and the tribute to Dr. Eli Glatstein.

Childhood leukemia, brain cancer on the rise
WebMD    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Childhood leukemia and brain cancer are on the rise, and exposure to chemicals in our environment such as chlorinated solvents and the head lice treatment lindane may be partially to blame, according to experts speaking at a conference call sponsored by Safer Chemicals, Healthy Families. The group is seeking to overhaul the 1976 Toxic Substances Control Act, but not everyone in the scientific community agrees that chemical exposure is connected to the uptick in childhood cancers. Some suggest that improvements in diagnosing childhood cancers also may have a role. More

MicroRNA suppresses prostate cancer stem cells, metastasis
FierceBiotech    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported in an advance online publication at Nature Medicine. "Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale for developing the microRNA miR-34a as a new treatment option for prostate cancer," said senior author Dean Tang, Ph.D., professor in MD Anderson's Department of Molecular Carcinogenesis. More

Early childhood exposure to radiation linked to thyroid cancer
Endocrine Today    Share    Share on FacebookTwitterShare on LinkedinE-mail
Early childhood exposure to radiation from multiple CT scans or other radiotherapy increases the risk for thyroid cancer, according to a study conducted at the University of Rochester Medical Center. Researchers collected health status data from a cohort of 1,303 patients who, as infants, had received lower-dose chest radiotherapy between 1926 and 1957 for treatment of an enlarged thymus. None of the patients were known to have cancer at the time. Researchers compared these results with the health status of the same group between 2004 and 2008. Health data on the non-irradiated siblings of these patients also were surveyed for the same years. More

Cancer costs to rise as aging US population, drugs stretch treatments
Bloomberg    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Cancer care may cost the U.S. two-thirds more in the next decade, potentially topping $200 billion as the population ages and drug prices rise. The tab last year was $125 billion, according to National Cancer Institute researchers who analyzed scenarios to determine future costs. By itself, the rising number of elderly Americans most vulnerable to cancer will push up the price to $158 billion by 2020, said Angela Mariotto, chief of data modeling at the NCI's Surveillance Research Program in Bethesda, Md. More

ASCO GI: Less invasive surgery viable for esophageal cancer
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Minimally invasive esophagectomy compared favorably with open surgery in patients with locally advanced esophageal cancer treated with chemoradiation, data from a clinical series suggest. The 46 patients treated thus far have a median one-year survival of 87 percent and a two-year survival of 65 percent. Complication and morbidity profiles have been as good or better than those associated with open surgery in trimodal therapy, according to a presentation at the Gastrointestinal Cancers Symposium. More

Chemistry unlocks drug delivery puzzle
UCF Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
University of Central Florida College of Medicine Professor Otto Phanstiel and two of his students recently presented their cancer-fighting research at an American Chemical Society regional meeting in New Orleans. ACS is the leading chemistry organization in America, with more than 150,000 members. As a medicinal chemist, Phanstiel uses organic chemistry to develop new therapeutics and drug-delivery systems. Phanstiel, graduate student Aaron Muth and undergraduate student Joseph Kamel presented their research on polyamines. Certain cancer cells use their polyamine transporters to feed off the polyamines of neighboring cells to grow, multiply and spread. This polyamine transport activity is especially prevalent in colon and pancreatic cancers. More

RadOnc Weekly
Colby Horton, Vice President of Publishing, 469.420.2601   Download media kit
Patrick McCoy, Senior Content Editor, 469.420.2603   Contribute news
This edition of RadOnc Weekly was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Jan. 26, 2011
Jan. 19, 2011
Jan. 12, 2011
Jan. 5, 2011

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063